Flt3 ligand does not differentiate between Parkinsonian disorders
Edina Silajdžić1, Radu Constantinescu, Björn Holmberg
1Brain Disease Biomarker Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden.
Summary
Cerebrospinal fluid flt3 ligand levels do not reliably differentiate between Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. This finding challenges previous reports suggesting its diagnostic utility for parkinsonian disorders.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Neurology
Background:
- Accurate diagnosis of parkinsonian disorders is difficult due to overlapping early symptoms.
- Validated biomarkers for early and precise diagnosis of multiple system atrophy and other parkinsonian disorders are lacking.
- Previous research suggested cerebrospinal fluid (CSF) flt3 ligand levels could distinguish Parkinson's disease (PD) from multiple system atrophy (MSA) with high accuracy.
Purpose of the Study:
- To investigate the utility of CSF flt3 ligand levels in differentiating between major parkinsonian disorders.
- To validate or refute previous findings on CSF flt3 ligand as a diagnostic biomarker for PD versus MSA.
Main Methods:
- CSF samples were collected from patients diagnosed with Parkinson's disease (n=37), multiple system atrophy (n=30), and progressive supranuclear palsy (n=19).
- Flt3 ligand concentrations in CSF were measured for all participants.
Main Results:
- No statistically significant differences in CSF flt3 ligand levels were observed among the Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy groups.
- The previously reported ability of flt3 ligand to differentiate PD from MSA was not replicated in this cohort.
Conclusions:
- CSF flt3 ligand levels are not a reliable biomarker for differentiating between Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
- Further research is needed to identify validated biomarkers for the early and accurate diagnosis of parkinsonian disorders.
Keywords:
Parkinson's diseasebiomarkerflt3 ligandmultiple system atrophyprogressive supranuclear palsyMore Related Videos
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015
8.1K
12:04Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue FACS-RTT to Determine the Cellular Origin of Radioactive Signal
Published on: September 10, 2021
1.8K
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
20
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
20
01:11Alterations in Muscle Tone lll
25
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
25
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:24Parkinson Disease l: Introduction
18
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
18
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:37Neural Regulation
34.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.6K